XERS
Xeris Biopharma Holdings, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 2 ▼ 1 insider sell $104.1K at $6.25
- Mar 30 to Apr 1 ▼ 2 days of insider sells: $159.9K by 2 insiders, avg $5.81
- May 1 ▼ 1 insider sell $103.8K at $6.23
- Jun 1 to Jun 4 ▼ 3 days of insider sells: $503.2K by 5 insiders, avg $6.05
- Jul 1 to Jul 7 ▼ 3 days of insider sells: $1.2M by 3 insiders, avg $8.17
- Aug 3 ▼ 2 insiders sell $253.8K at $8.01
- Aug 12 ▼ 1 insider sell $42.5K at $8.50
- Sep 1 ▼ 3 insiders sell $311.2K at $8.49
- Sep 28 to Oct 1 ▼ 2 days of insider sells: $594.9K by 3 insiders, avg $9.65
- Nov 2 to Nov 5 ▼ 2 days of insider sells: $772.7K by 3 insiders, avg $11.04
- Nov 5 ▲ Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and abov…
- Nov 5 ▲ Earnings: XERS Q3 2026 Earnings: EPS $0.06 (+144.9% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
8 insiders sold $4.1M.
- InstitutionsBULLISH
Q3 2026: 30 added (2 new), 16 trimmed or exited.
- AnalystsBULLISH
11 of 13 rate it Buy or better. Median target $18.00 (+8%).
- EstimatesRISING
Current-quarter EPS estimate $0.055 → $0.070 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +11.9% to 8.99M shares. 4.3 days to cover, ≈4.9% of shares.
- TrendUPTREND
58% above its 50-day average. New closing high $16.70 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 6.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| JPMORGAN CHASE & CO | DOUBLED | $23.8M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $16.2M |
| FIRST TRUST ADVISORS LP | DOUBLED | $13.4M |
| HRT FINANCIAL LP | DOUBLED | $10.4M |
| FMR LLC | ADD | $9.8M |
| UBS Group AG | TRIM | $7.5M |
| ROYCE & ASSOCIATES LP | ADD | $5.6M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $5.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is inside the target range. Median implies +8%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | Barclays MAINTAIN | Overweight |
| Nov 6, 2026 | Oppenheimer REITERATE | Outperform |
| Nov 6, 2026 | Piper Sandler REITERATE | Neutral |
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 6, 2026 | Barclays MAINTAIN | Overweight |
| Sep 10, 2026 | Leerink Partners MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
McCulloch Kevin See Remarks Nov 5, 2026 | SELL | $312.2K |
Pieper Steven See Remarks Nov 2, 2026 | SELL | $51.2K |
Hecht Beth See Remarks Nov 2, 2026 | SELL | $255.8K |
Taddese Menassie Director Nov 2, 2026 | AWARD | $320.3K |
Taddese Menassie Director Nov 2, 2026 | AWARD | 22,365 sh |
McCulloch Kevin See Remarks Nov 2, 2026 | SELL | $153.5K |
Pieper Steven See Remarks Oct 1, 2026 | SELL | $47.0K |
Hecht Beth See Remarks Oct 1, 2026 | SELL | $156.8K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $0.07 | $0.06–$0.08 | +110.0% | $119.0M |
| Next Q | $0.03 | $0.02–$0.04 | +20.0% | $115.9M |
| Current FY | -$0.01 | -$0.04–$0.03 | +85.2% | $401.5M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
25 filings · 4 bullish · 1 bearish · 20 neutral- NEUTRAL CLUSTERNov 6, 2026
Three Xeris insiders sold a total of $619K in open-market sales over a week, including a sale by…
The sales are small relative to market cap and all under 10b5-1 plans, so they do not signal a change in insider conviction. Monitor next insider filings for any unplanned open-market sales that…
- NEUTRAL 144Nov 5, 2026
Kevin McCulloch, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 25,000…
The sale is small relative to market cap and appears to be part of a pre-existing 10b5-1 plan for tax or diversification purposes. Monitor for any acceleration of insider selling beyond the plan's…
- BULLISH 8-KNov 5, 2026
Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and above the $101.7M consensus…
The raised 2026 guidance and significantly increased 2030 revenue outlook signal accelerating commercial momentum, particularly from Recorlev. Monitor the XP-8121 Phase 3 Cornerstone study…
- NEUTRAL CLUSTERNov 4, 2026
Two Xeris Biopharma officers sold a combined $409K in open-market sales on November 2, 2026, both…
The sales are small and pre-planned, providing no new signal about the company's outlook. Monitor the next earnings release for any change in fundamentals or insider activity.
All XERS filing & press-release reports (25)
- CLUSTER reportNov 6, 2026
- 144 reportNov 5, 2026
- 8-K reportNov 5, 2026
- CLUSTER reportNov 4, 2026
- 3 reportNov 4, 2026
- 144 reportNov 2, 2026
- 8-K reportNov 2, 2026
- SC 13G/A reportOct 30, 2026
- 8-K reportOct 14, 2026
- CLUSTER reportOct 2, 2026
- 144 reportOct 1, 2026
- 8-K reportSep 9, 2026
- CLUSTER reportSep 1, 2026
- 8-K reportAug 6, 2026
- CLUSTER reportAug 4, 2026
- CLUSTER reportJul 7, 2026
- 8-K reportJun 30, 2026
- CLUSTER reportJul 2, 2026
- 3 reportJul 2, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportJun 5, 2026
- CLUSTER reportJun 5, 2026
- 144 reportJun 3, 2026
- 144 reportJun 4, 2026
- 8-K reportFeb 27, 2026